A phase I/II study, comprising 97 advanced ALK-positive, NSCLC patients given 225 mg ensartinib daily, revealed rashness, nausea, vomiting, pruritus and fatigue as frequent aftermaths. Here, ALK is linked to non-small cell lung carcinoma.